Vaccination against atherosclerosis

Area of Science:

• Cardiovascular Science
• Immunology
• Vaccinology

Background:

• Atherosclerosis is a leading cause of global mortality, characterized by chronic inflammation and significant residual cardiovascular risk despite statin therapy.
• The autoimmune component of atherosclerosis presents an opportunity for immunologic interventions, particularly vaccination.
• Current treatments leave a residual inflammatory risk, necessitating novel therapeutic strategies.

Purpose of the Study:

• To review the potential of vaccination as an immunologic approach to combat atherosclerosis.
• To focus on two distinct vaccine strategies: antibody-inducing and regulatory T cell-inducing vaccines.
• To highlight candidate antigens and their efficacy in preclinical atherosclerosis models.

Main Methods:

• Review of existing literature on atherosclerosis, immunology, and vaccine development.
• Analysis of preclinical studies investigating atherosclerosis vaccine candidates in animal models.
• Categorization of vaccines based on their immunologic mechanism (antibody-inducing vs. regulatory T cell-inducing).

Main Results:

• Several candidate antigens have been identified for atherosclerosis vaccine development.
• Vaccine strategies targeting atherosclerosis have demonstrated efficacy in reducing disease progression in animal models.
• Two primary vaccine-induced immune responses are discussed: antibody induction and regulatory T cell induction.

Conclusions:

• Vaccination offers a specific, non-immunosuppressive, and potentially long-lasting approach to managing atherosclerosis.
• Both antibody-inducing and regulatory T cell-inducing vaccines represent viable strategies for mitigating atherosclerosis.
• Further research into atherosclerosis vaccines could significantly reduce the global burden of cardiovascular disease.